{"ok":true,"framework":"Phil Analyst — Evidence + Narrative","drafted_for":"ASRC Federal Leadership / Chip Terry","audience_note":"Draft leadership matrix — align with FPDS / USAspending signals in DuckDB. CQM II is framed as clinical-operations complement to HRPO research-oversight work (MRDC clinical translation).","rows":[{"id":"dmix_diss","opportunity_node":"DMIX / DISS / Data Exchange","target_vehicle":"GSP / WF3","pwin":0.85,"strategic_recommendation":"GO (INVEST)","evidence_logic":"Anchor: $90M+ technical provenance. ASRC owns the data plumbing."},{"id":"gsp_to13_walter_reed","opportunity_node":"GSP TO #13 (Walter Reed)","target_vehicle":"GSP","pwin":0.75,"strategic_recommendation":"GO (INVEST)","evidence_logic":"Target: Lawelawe expiry (Sept 2026). High regional transition probability."},{"id":"workforce_3","opportunity_node":"Workforce 3.0","target_vehicle":"WF3 IDIQ","pwin":0.55,"strategic_recommendation":"SELECTIVE GO","evidence_logic":"Team: Sub to BCG (incumbent). Focus on Technical Implementation node."},{"id":"dencom_cds2","opportunity_node":"DENCOM CDS II","target_vehicle":"Recompete","pwin":0.5,"strategic_recommendation":"SELECTIVE GO","evidence_logic":"Niche: Lower complexity than GENESIS; clean entry path for ASRC."},{"id":"hcds_genesis","opportunity_node":"HCDS (GENESIS) Sustainment","target_vehicle":"DHMS IDIQ","pwin":0.4,"strategic_recommendation":"SUB-ONLY","evidence_logic":"Risk: Leidos / Accenture iron-triangle incumbency. Sub for integration only."},{"id":"cqm_ii","opportunity_node":"DHA Clinical Quality Management (CQM) II","target_vehicle":"Recompete / IDIQ (8(a) set-aside — verify solicitation)","pwin":0.42,"strategic_recommendation":"SELECTIVE GO — MUST WATCH (2027–28)","evidence_logic":"Clinical translation play: past ASRC HRPO work is research integrity (IRB, human-subject safety); CQM II is MHS clinical operations — accreditation, credentialing, privileging, performance improvement, and clinical measurement across MTFs — not a copy of HRPO. Closing the loop: protocols HRPO helps protect should become measurable clinical standards; CQM II is a natural vehicle for analytical and programmatic support to operationalize outcomes. Federated / patient-centered data (Sync.MD-class interoperability) supports specialized clinical-measurement requirements if scope aligns. Competitive: 8(a) set-aside; align with ASRC/BDR Joint Venture (Venture 5) posture where applicable — verify vehicle and teaming rules on SAM. Differentiation: incumbents often emphasize accreditation box-checking (e.g. Joint Commission); capture intelligence / knowledge-graph story (e.g. RunaiVa) can argue for automation and real-time quality monitoring vs manual reporting — evidence-dependent. SAM notice id cited in BD narrative: HT001125RE034 — confirm active posting and amendments on SAM.gov."},{"id":"sync_md","opportunity_node":"Sync.MD (PHR / VBA)","target_vehicle":"TBD","pwin":0.15,"pwin_display":"<0.20","strategic_recommendation":"KILL (NOISE)","evidence_logic":"Fail: Zero FPDS transaction signal. High B&P waste risk."},{"id":"care_coord_ebms","opportunity_node":"Care Coordination / EBMS-D","target_vehicle":"J-6 RMOPS","pwin":0.2,"pwin_display":"<0.25","strategic_recommendation":"KILL (NOISE)","evidence_logic":"Fail: Fragmented structure; low alignment with ASRC Core Five strategy."}]}